-
New technology pulls out 'silent killer' in tumor stem cells
Time of Update: 2021-02-24
Surprisingly, these tumor stem cells are usually in a resting state, with low telomerase activity and the ability to maintain relatively short telomere lengths due to their non-proliferation.
-
Tagrisso leads other drugs in first-line lung cancer survival
Time of Update: 2021-02-24
Tagrisso already dominates the second-tier egfr-positive non-small cell lung cancer market, and AstraZeneta has been trying to push new drugs to the front line, which appears to have had some success in many markets.
-
ASCO GU 2021: IL-15R alphaFc super-excited agent N-803 studied in patients with NMIBC bladder cancer in place who responded to BCG (QUILT 3.032 trial
Time of Update: 2021-02-24
in BCG non-reactive CIS patients (with or without Ta or T1 disease), all patients in the queue received in-bladder N-803 plus BCG, which met the standard induction/maintenance treatment options.
-
ASCO GU 2021: What is the effectiveness of immunotherapy in the first line of metastatic renal cell carcinoma
Time of Update: 2021-02-24
plus ipilimumab combination and the immunotherapy/VEGF inhibitor combination in the IMDC moderate/low-risk population. the combination of severe immuno-related adverse events and improvements in total survival and next treatment time related to nivolumab plus monoantitherapy and immunotherapy/VEGF inhibitors are reasonable first-line strategies
-
Jilin Petrochemical has built a styrene blocker evaluation device
Time of Update: 2021-02-24
China Coatings Network News: Jilin Petrochemical Research Institute styrene blocker evaluation device has been completed, with the plant evaluation of the whole process simulation test conditions, the project has entered the pilot production and industrialization application stage.
-
Takeda protease inhibitor Ninlaro Phase 3 test reached the main end of the test
Time of Update: 2021-02-24
Today, Takeda announced that its protease inhibitor Ninlaro (ixazomib) as a first-line maintenance therapy, in the treatment of adult patients with multiple myeloma (MM) who have not received stem cell transplant therapy in phase 3 trials
-
The application for the listing of regenerant biology Terripley single anti-new anti-adhesive disease was accepted
Time of Update: 2021-02-24
On February 18, Junshi Bio announced that the company had received a "notice of acceptance" approved by the State Drug Administration, and that the new adaptation application for Ripley monoantithermal combination chemotherapy for advanced first-line
-
Dig Dis Sci: The effect of conservative maintenance therapy for eosinophilic esopheditis on the recurrence of the disease
Time of Update: 2021-02-24
a retrospective analysis of patients with eosinophilic esopheditis, they found a significant reduction in the proportion of patients receiving maintenance therapy (PPI, steroids, or dietary rejection) who needed repeated dilation, the authors concluded.
-
Somaglutide combined with cilofexo/firsocostat treatment NASH II with positive results
Time of Update: 2021-02-24
The study reached the main clinical endpoint, and patients with NASH with mild and moderate liver fibrosis were well-resistant to all treatment options. most common adverse events (AEs) are gastrointestinal reactions. itching symptoms
-
The FDA has approved Bayer nubeqa ® for the treatment of patients with adenocarcinoma
Time of Update: 2021-02-24
today, Bayer announced FDA approval for Nubeqa® (darolutamide) for the treatment of patients with non-metastatic desopathic prostate cancer (nmCRPC).
-
Nat Commun: Dual target polyamine synthesis and ingestion: a potential treatment strategy for diffuse endogenetic brain bridge glioma
Time of Update: 2021-02-24
studies have shown that DIPG cells can compensate for the inhibition of ODC1 by raising the expression of the polyamine transport protein SLC3A2.
-
Thorax: Analysis of the efficacy of the treatment of COVID-19 with lye inhibitors
Time of Update: 2021-02-24
result, the tocilizumab treatment in the prospective study was associated with lower mortality, but other outcomes were inconclusive.
-
FDA approves Red Hill's innovative therapy, Talicia, for listing
Time of Update: 2021-02-24
Talicia is an FDA-approved helicobacter pyridobacteria removal therapy based on rifabutin designed to address helicobacter pyridosis resistance to antibiotics commonly used in standard care therapies.
-
Kun Pharmaceutical Group IDH1 selective inhibitors were approved by NMPA clinical trials
Time of Update: 2021-02-24
but not limited to intra-hepatic bile tube tumors. IDH is a speed-limiting enzyme involved in cellular energy metabolism in the human body, and studies have shown that intracellular carcinogenic metabolites caused by IDH mutations promote tumor
-
Xinda Bio and Sanoki have reached a clinical partnership to develop Xindili monoantigen combination therapy
Time of Update: 2021-02-24
Bioinnovatable Oncology Drug Dabershu® (recombinant all-human source anti-PD-1 monoclonal antibody, English trademark: Tyvyt®, chemical generic name: Xindili monoanti-injection) joint clinical development of drugs, the proposed development of the adaptive
-
GSK submits a application for a new drug for daprodustat to MHLW Japan
Time of Update: 2021-02-24
recently, GlaxoSmithKline (gsk) submitted a new drug application (nda) to japan's Ministry of Health, Labour and Welfare (mhlw) for approval of oral hypooxygenated factor proline hydroxygen inhibitor (hif-phi) daprodustat to treat renal anemia caused by chronic kidney disease (ckd).
-
Rinvoq has been approved by the European Union to treat rheumatoid arthritis
Time of Update: 2021-02-24
) to treat adult patients with moderate to severe active rheumatoid arthritis who do not respond adequately or to the MTX. Currently, an estimated 400,000 people in the UK suffer from rheumatoid arthritis, most of whom are not in remission. （cyy123.com）
-
Pharmaceutical companies' China revenue, Top7 announced (with list
Time of Update: 2021-02-24
achieved positive growth, with Lilly accounting for the highest increase, at 19 per cent. (File Photo: Pharmaceutical Rubik's Cube) Star Pharmaceuticals contributed big on February 12, when British pharmaceutical giant AstraZeneta released its fourth
-
Bronger Ingham gave up BI1467335 for NASH adaptation
Time of Update: 2021-02-24
biomarkers", it was found in Phase 1 tests after the suspension that receiving the drug would increase the "risk of drug interactions in NASH patients", a side effect that the two companies are currently unable to address. The researchers did not specify
-
Ardelyx's Phase 3 trial to treat high phosphorusemia has reached its end
Time of Update: 2021-02-24
Once approved, Tenapanor could be the basic therapy for patients on CKD dialysis with elevated blood phosphorus concentrations, Ardelyx said.
